Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

ABSTRACT:

Background and objectives

In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, renal function (estimated GFR), and BP over 5 years between treatment groups.

Design, setting, participants, & measurements

A total of 4351 recently diagnosed, drug-naïve patients with type 2 diabetes were treated and followed for up to 5 years with rosiglitazone, metformin, or glyburide and were examined with periodic assessments of albumin/creatinine ratio (ACR), modification of diet in renal disease (MDRD)-estimated GFR, and BP.

Results

The ACR rose slowly with metformin. It fell wit

SUBMITTER: Lachin JM 

PROVIDER: S-EPMC3087768 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature